Company News

Peptest, a groundbreaking non-invasive diagnostic tool for reflux disease, has officially entered the Chinese market after receiving medical device registration from the National Medical Products Administration (NMPA). This launch coincides with the release of China's first multidisciplinary expert...

Pepfast, our rapid and non‑invasive reflux test, has been commercialized in Hong Kong through a partnership with The HomeCare Medical Limited. The product received NMPA registration in May 2025 and was launched immediately. By July 2025, it had already entered the Hong Kong market through this coll...

Pepfast, our second‑generation, non‑invasive reflux diagnostic test, received NMPA registration in China in May 2025. Just seven months later, in December 2025, the product secured both CE marking and FDA clearance—enabling access to markets across Europe and the United States.   Pepfast...

A comprehensive suite of reflux management solutions attracted significant attention from a global medical audience at a major healthcare exhibition in Thailand. The products were presented by a joint team of R&D engineers from RD Biomed Ltd (UK) and Maxhealth Innovative Meditech, engaging with...